Dauneon (Daunorubicin) 20mg

Dauneon (daunorubicin 20mg) is a chemotherapy medication used to treat certain cancers. It belongs to the anthracycline class and works by slowing or stopping cancer cell growth. This single-dose vial is designed for intravenous use in clinical settings.

Strength

20mg

Pack Size

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Dauneon is primarily used in cancer treatment, including acute myeloid leukemia and certain solid tumors. It may also be prescribed for other conditions as determined by a healthcare provider. Patients often ask, 'what is daunorubicin used for' in discussions about chemotherapy options. This medication targets rapidly dividing cells to help control disease progression.

Side Effects

Dauneon may cause temporary side effects such as nausea, hair loss, or fatigue during treatment. Some patients experience changes in urine color due to the medication's properties. These effects vary by individual and typically resolve after therapy completion. Always discuss persistent symptoms with your healthcare team.

Precautions & Warnings

Dauneon requires careful handling due to its cytotoxic nature. It should only be administered by trained medical professionals in appropriate clinical settings. Patients should inform their provider about all current medications and health conditions before starting treatment. Regular monitoring is essential during therapy.

Avoid Interactions

Dauneon may interact with other medications, including certain antibiotics, blood thinners, or heart medications. Alcohol and herbal supplements should be avoided unless approved by a doctor. Patients should disclose all substances to their healthcare provider to prevent potential complications. Monitoring for interactions is standard during chemotherapy.

Frequently Asked Questions

Daunorubicin 20mg is used to treat certain cancers, including acute myeloid leukemia and some solid tumors.

Dauneon is given as an intravenous infusion by healthcare professionals in a clinical setting.

Common side effects may include nausea, hair loss, and fatigue during treatment.

Always consult your doctor before combining daunorubicin with other drugs or supplements.

Daunorubicin may harm an unborn baby; discuss risks with your healthcare provider if pregnant or planning pregnancy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.